The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer

Yousif A. Kariri1,2 · Mansour Alsaleem1 · Chitra Joseph1 · Sami Alsaeed1 · Abrar Aljohani1 · Sho Shiino1 · Omar J. Mohammed1 · Michael S. Toss1 · Andrew R. Green1 · Emad A. Rakha1,3

Received: 20 May 2020 / Accepted: 28 September 2020 / Published online: 19 October 2020
© The Author(s) 2020

Abstract
Background Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 15 (ISG15) LVI status. Thus, we explored the prognostic significance of ISG15 in BC.
Methods The prognostic significance of ISG15 mRNA was assessed in METABRIC (n = 1980), TCGA (n = 854) and Kaplan–Meier Plotter (n = 3951). ISG15 protein was evaluated using immunohistochemistry (n = 859) in early-stage invasive BC patients with long-term follow-up. The associations between ISG15 expression and clinicopathological features, expression of immune cell markers and patient outcome data were evaluated.
Results High mRNA and protein ISG15 expression were associated with LVI, higher histological grade, larger tumour size, hormonal receptor negativity, HER2 positivity, p53 and Ki67. High ISG15 protein expression was associated with HER2-enriched BC subtypes and immune markers (CD8, FOXP3 and CD68). High ISG15 mRNA and ISG15 expressions were associated with poor patient outcome. Cox proportional multivariate analysis revealed that the elevated ISG15 expression was an independent prognostic factor of shorter BC-specific survival.
Conclusion This study provides evidence for the role of ISG15 in LVI development and BC prognosis. Further functional studies in BC are warranted to evaluate the therapeutic potential of ISG15.

Keywords Interferon-stimulated gene 15 · ISG15 · Breast cancer · Progression · Prognosis

Introduction

Although the progression of breast cancer (BC) involves a complicated multi-step process, migration is one of the principal steps that is responsible for tumour progression from the in situ to the invasive stage, stromal and lymphovascular invasion (LVI) and development of metastasis. As the outcome of cancer is largely determined by its ability to produce distance metastasis, understanding the mechanisms underlying BC metastasis and investigations of LVI is warranted. LVI is a strong prognostic factor in BC, particularly in the early-stage disease and is associated with cancer-related mortality [1–4]. However, identifying the molecular mechanisms underlying LVI and its driver genes that can be targeted to prevent or reduce metastasis remains a challenge [1].

A previous study, reported by our team, has elucidated the mechanistic association between gene expression and LVI positivity [5]. The 99 differentially expressed genes (DEGs)
that showed association with LVI exhibited 42 significantly upregulated genes and 57 significantly downregulated genes based on weighted average differences (WAD) [5, 6]. Furthermore, when gene set enrichment analysis (GSEA) [7] was applied to the molecular panel previously identified by WAD approach, cell migration was the top of the main regulators of the gene panel.

Interferon-stimulated gene 15 (ISG15) encodes ISG15 (ubiquitin-like protein) which is highly expressed in almost all tumours and is stimulated by type I interferons. As a consequence of immune cell infiltration into the tumour stroma and because these cells are the main source of interferon α and β, this may lead to increased ISG15 expression in tumour cells [8]. Moreover, ISG15 is detected as a conjugated protein that links to multiple target proteins in what is called ISGylation process, but it can also be found in free or unconjugated status. In ISGylation, the ISG15 protein attaches and modifies a target protein in a similar way to the ubiquitylation process [9]. ISGylation plays a key role in the inhibition of protein translation either via inhibiting eIF2α by ISGylation of dsRNA-dependent protein kinase [10] or via enhancing the cap-structure-binding activity of the ISGylated translational suppressor 4EHP [11]. ISG15 has been reported to play a significant role in tumour micro-environment via enhancing T cells, B cells and epithelial cell lines cytokines [12]. A previous study has suggested that the secretion of ISG15 has an influence on T and NK cells to prompt IFNγ production and may have a significant role in the innate immunity [13]. Moreover, the extracellular ISG15 acts as an immune adjuvant that promotes antigen-specific CD8 + T cell tumour immunity [14]. In ovarian cancer, ISG15 can stimulate CD8 + T cell proliferation by activating NK cells, which enhance the cytokines production such as IL2 and IFNγ [15]. ISG15 is also highly correlated with the expression of the macrophage marker CD68 and it appears to mediate the cellular expression of multiple cytokines in macrophage through the regulation of p38 phosphorylation [16].

High ISG15 has been shown to be accompanied by certain oncogenic proteins facilitating tumour oncogenesis by inhibiting cells that control apoptosis in both primary tumour (with high α and β interferons) and during metastasis (when the interferons decrease) [8]. However, its role in LVI and cancer metastasis remains unclear. A previous study that has investigated the role of ISG15 in tumour progression and invasion suggested that high expression of ISG15 enhances the cancer cell migration invasion and metastasis [9]. ISG15 alters multiple proteins, including focal adhesion protein, action binding or modifying proteins to improve their function or increase their stability to facilitate the cancer cell migration, such as binding with Rac1 in oral squamous cell carcinoma [17]. The upregulation of ISG15 was identified as a critical gene strongly associated with BC progression and metastasis via modulating the cell architecture and enhancing the cancer cell motility [9]. Moreover, BC cell lines showed significantly elevated expression of ISG15 compared with normal cell lines, and the knockdown of ISG15 expression was reduced ZR-75-1 cell motility in cell migration assay compared to the wild type [18]. However, the biological and prognostic value of ISG15 expression in BC remains to be defined.

In our previous studies aiming to identify the driver of LVI in BC [1, 5], ISG15 was in the differentially identified genes associated with LVI. This study aimed to validate the prognostic significance of ISG15 defined by our gene signature [5] and evaluate its association with well-established prognostic variables including LVI, relevant biomarkers related to ISG15 function/expression and patient outcome.

**Materials and methods**

**Study cohorts**

ISG15 mRNA expression was assessed using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets (n = 1980) [19] and The Cancer Genome Atlas (TCGA) (n = 854) [20]. The Illumina Human HT-12 v3 platforms (Illumina, Inc., San Diego, USA) were used in the METABRIC to analyse/evaluate mRNA extracted from primary tumour samples. In TCGA, RNASeqV2 data and clinicopathological information provided by cBioPortal website were used [21, 22]. The cut-off point was determined using the median for both METABRIC cohort (9.5) and TCGA cohort (1007) to categorise into high and low subgroups. For further validation of the prognostic significance of ISG15 in BC, an online analytical module the Kaplan–Meier Plotter (n = 3951) [23] was employed.

ISG15 protein expression was evaluated using a well-characterised cohort of BC (n = 667) collected from patients presented to Nottingham City Hospital, NHS Trust between 1989 and 1998 as previously described [24]. Patients were classified for management purposes into clinically relevant groups based on the Nottingham Prognostic Index (NPI) and Oestrogen Receptor (ER) status as previously described [2]. Patients were divided into two subgroups according to their NPI level; patients with NPI ≤ 3.4 received no adjuvant therapy, whereas patients who had NPI > 3.4 received chemotherapy if ER status negative and received tamoxifen.
as a hormonal therapy if ER status was positive. Classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were used as a therapy for patients who lacked ER expression and were eligible to receive chemotherapy. This was in accordance with the local BC management protocol during the period of the study patients’ presentation. Patients in this study did not receive neoadjuvant therapy or anti-human epidermal growth factor receptor 2 (HER2)-targeted therapy.

Data on ER, progesterone receptor (PR), Ki67 expression and HER2 status were available as previously published [25, 26]. ER and PR cut-off points were previously defined as ≥ 1% [26–28]. Ki67 cut-off was previously defined as ≥ 10 [29]. Information on the clinical history, clinicopathological variables, outcome and therapy was collected from patients’ clinical notes. Outcome data included the time of development of BC and BC-specific survival (BCSS) where the latter is defined as the time in months from the date of primary surgery to the time of the patient’s death due to BC.

For further understanding the protein interactions of high ISG15, available protein data from our cohort on tumour prognostic markers (P53 and Ki67), epidermal growth factor receptor (EGFR), EMT-related marker (E-cadherin (CDH1)), stem cell marker (CD44) and stromal T infiltrative factor receptor (EGFR), EMT-related marker (E-cadherin (CDH1)), stem cell marker (CD44) and stromal T infiltrative lymphocyte markers (TILs) (CD8, FOXP3 and CD68) were included in this study as per previous publications [29–35] (Supplementary Table 1).

**Immunohistochemistry (IHC)**

ISG15 protein expression was evaluated using immunohistochemistry preceded by validation of the ISG15 antibody specificity using Western blot [rabbit polyclonal antibody (ab227541); Abcam Company, UK] cell lysates of MCF7, SKBR3, MB-MDA-231 and MB-MDA-468 (obtained from the American Type Culture Collection; Rockville, MD, USA). The rabbit anti-ISG15 antibody (1/800) was incubated overnight at 4 °C and after being exposed to an appropriate secondary antibody, a single band at approximately 42 KDa was detected using fluorescent secondary antibodies at (1:15,000) (IR Dye 800CW donkey anti-rabbit and 680RD donkey anti-mouse, LI-COR Biosciences, UK). The mouse anti-β-actin antibody (A5441, Sigma-Aldrich; Clone AC-15; Sigma, UK) at 1:5000 was used as a house-keeping protein and showed a band at approximately 42 KDa (Supplementary Fig. 1A and B). Moreover, as recommended by the manufacturer, HELA cell lysate was used as the positive control and the specificity of the antibody was validated with a single specific band at the predicted molecular weight (~42KDa) (Supplementary Fig. 1C).

To assess the distribution of ISG15 expression within the BC tissue, 14 full-face sections of BC cases, representative of various molecular subtypes and tumour grade, were stained prior to TMA staining and evaluation. We have observed that ISG15 was homogenously distributed throughout these tissue sections, which indicate suitability of TMA to assess expression of ISG15 in breast cancer epithelial tumour cells. TMA Grand Master® (3D HISTECH®, Budapest, Hungary) was used to array the tumour samples into TMAs as previously described [36]. Heat-induced citrate antigen retrieval (pH 6.0) was utilised and samples were incubated with the ISG15 antibody (1:500) at room temperature for 1 h. Finally, ISG15 immunoreactivity was detected using the Novolink Max Polymer Detection kit (Leica, Newcastle, UK) and following the manufacturer’s instructions. Normal kidney tissue was used as a positive tissue control (Supplementary Fig. 1D).

**Scoring**

Nanozoomer scanner (Hamamatsu Photonics, Welwyn Garden City, UK) was used to scan the stained sections with high-resolution digital images at ×20 magnification. Modified H-score was manually used to evaluate the ISG15 cytoplasmic immunoreactivity by calculating the staining intensity and percentage of positivity. The proportion of tumour cells (0–100) was multiplied by the staining intensity (0–3) and the final scores were obtained, giving a range of 0–300 [37]. Some TMA cores were regarded as non-informative if they contain less than 15% tumour cells or when they are folded cores. A blind double scoring was performed by two researchers (YK and SA) to evaluate the interobserver concordance. Intraclass correlation coefficient (ICC) concordance showed good reliability between both observers (0.85) and discordant cases were rescorded by both observers to reach a final agreement. To categorise high and low subgroups, the median was used to generate cut-off for ISG15 protein (35-H-score) expression levels.

**Statistical analysis**

Statistical analysis was accomplished by using SPSS (IBM SPSS Statistics, Version 24.0). Pearson correlation test was used to assess the association between ISG15 mRNA expression and the expression of a set of genes correlated with epithelial–mesenchymal transition (EMT) [38] and cancer cell migration [24] (CDH1 (E-cadherin), CDH2 (N-cadherin), Transforming Growth Factor Beta 1 (TGFBI), Twist Family BHLH Transcription Factor 2 (TWIST2), Twist Family BHLH
Transcription Factor 2 (TWIST1), Zinc Finger E-box Binding Homeobox2 (ZEB2), Zinc Finger E-box Binding Homeobox1 (ZEB1), Snail family Transcriptional Repressor 2 (SLUG), SNAI1, Nuclear Factor Kappa B Subunit 1 (NFKB1), Lethal Giant Larvae Homolog 2 (LLGL2), Glycogen synthase 3 Beta (GSK3B), Crumbs Cell Polarity Complex Component 1 (CRUMBS) and Catenin Beta 1 (CTNNB1). The association between ISG15 mRNA expression and the expression of Matrix Metalloproteinase (MMPs) genes in the METABRIC cohort was also analysed. Chi-square test was used to evaluate the correlation between the clinicopathological features and ISG15 protein expression where data are available. The prognostic significance of ISG15 expression was determined via Kaplan–Meier survival curves using log-rank test. Multivariate survival analysis was assessed by using Cox proportional hazard method. Both ISG15 mRNA/protein expressions were abnormally distributed and therefore were dichotomised by median cut-off value. The statistical significance of clinicopathological factors and survival was defined by \( p \) value < 0.05 (two-tailed). This work was performed according to REMARK guidelines or tumour prognostic study [39] and approved ethically by the North West–Greater Manchester Central Research Ethics Committee under the title: Nottingham Health Science Biobank (NHSB), reference number 15/NW/0685.

**Bioinformatics investigation and pathway analysis**

The molecular biology of ISG15 mRNA expression was investigated at the transcriptomic level using a subset of METABRIC and TCGA cohorts [19]. Regardless of LVI status, the restriction was based on the PAM50 molecular classification using only HER2-enriched and luminal B cases as our proteomic and transcriptomic revealed a strong association of ISG15 expression with LVI and patient outcome in these two subtypes. Nevertheless, the differential gene expression (DGE) analysis was performed using the Robina implementation of Edge-R statistical tool [40]. The dichotomisation of cases into high versus low groups relied on the median of ISG15 mRNA expression in both cohorts. Henceforth, high expression of ISG15 mRNA in the METABRIC cohort is displayed in 364/728 cases (50.0%), whereas in the TCGA cohort, ISG15 mRNA high expression was observed in 137/275 cases (49.8%). DGE was performed in two categories: (A) cases harbouring high ISG15 mRNA expression against cases harbouring low ISG15 mRNA expression within the METABRIC cohort and (B) cases harbouring high ISG15 expression against cases harbouring low ISG15 mRNA expression within the TCGA cohort. Common genes that were found to drive the ISG15 mRNA expression in both the METABRIC and TCGA cohorts were identified using the Venny 2.0 online tool [41].

To explore targetable, the online public available web-based Gene ontology enrichment analysis and visualisation tool (GORILLA) [42] gene set analysis tool was used to identify differentially regulated canonical pathways. This pathway analysis calculated the significantly enriched pathways for the genes common to ISG15 mRNA overexpression in both METABRIC and TCGA cohorts based on genes differentially expressed at the \( p < 0.05 \) level and generated by Robina analysis, including only unbiased hits with a significant enrichment score [42].

**Results**

**ISG15 mRNA expression and association with clinicopathological parameters and outcome**

In both METABRIC and TCGA cohorts, high ISG15 mRNA expression was correlated with LVI and other variables of poor prognosis, including high tumour grade, hormone receptor negativity [ER and PR], HER2 positivity and expression of EGFR and stem cell CD44) marker (Table 1). High ISG15 expression was also associated with larger tumour size and positive nodal status in the METABRIC cohort (Table 1). Moreover, when we distributed the mRNA expression of ISG15 according to histological tumour subtypes, high mRNA expression of ISG15 was significantly associated with ductal no special type (NST) BC compared to lobular BC subtype in the METABRIC cohort \( (p < 0.001) \), but not in the TCGA cohort \( (p = 0.710) \) (Table 1).

High ISG15 mRNA expression was positively correlated with the expression of EMT-related markers LLGL2 and CTNNB1 (Table 2) and with multiple MMPs biomarkers including MMP9, MMP11, MMP13, MMP21 and MMP28 (Table 2).

In METABRIC and KM-Plotter dataset, outcome analysis indicated an association between high ISG15 mRNA expression and shorter BCSS \((p < 0.001, \) Fig. 1a and b). In TCGA, high ISG15 mRNA expression showed similar trend, but did not reach statistical significance \((p = 0.335, \) Fig. 1c).

When we stratified the METABRIC mRNA cohorts based on LVI and HER2 status, high ISG15 mRNA expression was associated with poor survival in LVI-positive subgroup \((p < 0.001, \) Fig. 1d) and in the HER2-positive subgroup \((p < 0.001; \) Fig. 1e). A trend towards similar associations with poor survival was observed in the TCGA cohort for both LVI-positive and HER2-positive cases that did not reach statistical significant \((p = 0.415, \) Fig. 1f and \( p = 0.174, \) Fig. 1g, respectively). Nonetheless, when
Table 1  Association of ISG15 mRNA expression with clinicopathological characteristics in the METABRIC (n = 1980) and TCGA (n = 895) datasets

| Parameters                          | METABRIC cohort | TCGA cohort |
|-------------------------------------|-----------------|-------------|
|                                    | Low ISG15  | High ISG15 | p value | Low ISG15  | High ISG15 | p value |
| Tumour size                         |               |            |         |               |            |         |
| ≤ 2.0 cm                           | 454 (53)     | 405 (47)   | 0.003   | 131 (31)     | 108 (45)   | 0.087   |
| > 2.0 cm                           | 526 (48)     | 575 (52)   |          | 297 (48)     | 318 (52)   |          |
| Nodal status                        |               |            |         |               |            |         |
| Negative                            | 543 (53)     | 492 (47)   | 0.018   | 216 (51)     | 207 (49)   | 0.606   |
| Positive                            | 492 (52)     | 496 (53)   |          | 210 (49)     | 216 (51)   |          |
| Histological grade                  |               |            |         |               |            |         |
| Grade 1 and 2                       | 551 (59)     | 390 (41)   | <0.001  | 268 (58)     | 196 (42)   | <0.001  |
| Grade 3                             | 389 (41)     | 562 (59)   |          | 141 (55)     | 211 (60)   |          |
| Tumour histological subtypes        |               |            |         |               |            |         |
| Ductal NST                          | 705 (46)     | 839 (54)   | <0.001  | 212 (48)     | 227 (52)   | 0.710   |
| Lobular                             | 105 (710    | 42 (29)    |          | 69 (52)     | 63 (48)    |          |
| Medullary-like                      | 20 (62)      | 12 (38)    |          | 15 (58)     | 11 (42)    |          |
| Special type                        | 139 (69)     | 64 (31)    |          | 14 (52)     | 13 (48)    |          |
| Lymphovascular invasion             |               |            |         |               |            |         |
| Negative                            | 482 (52)     | 448 (48)   | 0.037   | 258 (46)     | 301 (54)   | 0.002   |
| Positive                            | 295 (47)     | 340 (53)   |          | 169 (57)     | 126 (43)   |          |
| Oestrogen receptor                  |               |            |         |               |            |         |
| Negative                            | 207 (44)     | 267 (56)   | 0.002   | 74 (40)      | 111 (60)   | 0.003   |
| Positive                            | 783 (52)     | 723 (48)   |          | 335 (52)     | 304 (48)   |          |
| Progesterone receptor               |               |            |         |               |            |         |
| Negative                            | 416 (44)     | 524 (56)   | <0.001  | 150 (44)     | 152 (56)   | 0.029   |
| Positive                            | 574 (55)     | 466 (45)   |          | 285 (52)     | 261 (48)   |          |
| Human epidermal growth factor receptor 2 |       |            |         |               |            |         |
| Negative                            | 883 (51)     | 850 (49)   | 0.025   | 298 (53)     | 296 (47)   | 0.013   |
| Positive                            | 107 (43)     | 140 (57)   |          | 54 (41)      | 79 (59)    |          |
| Epithelial growth factor receptor   |               |            |         |               |            |         |
| Negative                            | 537 (54)     | 453 (46)   | <0.001  | 245 (57)     | 182 (43)   | <0.001  |
| Positive                            | 453 (46)     | 537 (54)   |          | 183 (43)     | 244 (57)   |          |
| CD44                                |               |            |         |               |            |         |
| Negative                            | 542 (55)     | 448 (45)   | <0.001  | 249 (58)     | 117 (42)   | <0.001  |
| Positive                            | 448 (45)     | 542 (55)   |          | 178 (42)     | 249 (58)   |          |

Significant correlations are in bold.
performing survival analysis to test the value of ISG15 mRNA expression on both the METABRIC and TCGA cohorts after restriction to the LVI-negative and HER2-negative cases, our data showed no statistical association with patients outcome ($p > 0.05$) (Supplementary Fig. 2A, B, C and D, respectively).

### ISG15 pathway analysis

Our DGE investigation identified a total of 807 differentially regulated genes associated with ISG15 mRNA expression in both cohorts. Within the METABRIC cohort, high ISG15 mRNA expression displayed 1401 overexpressed and 1874 downregulated genes. Likewise, in the TCGA cohort, high ISG15 mRNA expression displayed 2389 overexpressed and 1872 downregulated genes. Remarkably, the overlapping of high and low DEGs of both cohorts between cases harbouring high ISG15 mRNA expression against cases harbouring low ISG15 mRNA expression in both cohorts included 490 common overexpressed and 317 common downregulated genes associated with ISG15 mRNA expression (Fig. 2a).

Analysis of the 490 commonly overexpressed genes identified over-represented gene ontology (GO) terms associated with epithelial cell migration which highlights the role of ISG15 in tumour oncogenesis. The common low-expressed genes showed no GO terms with enrichment $p$ value above the specified $p$ value threshold ($p = 0.001$) (Fig. 2b) (Supplementary Table 2).

### ISG15 protein expression

The expression of ISG15 showed significant correlation between transcriptomic level and protein level using Pearson correlation test ($p = 0.042$). Within the 14 BC full-face sections, normal breast terminal duct lobular unit (TDLU) showed faint to weak expression of ISG15 compared to higher expression of ISG15 in invasive breast tissue (Supplementary Fig. 1E and F, respectively). For dichotomisation into negative/low and high expression, the median H-score 35 was used. Out of 674 informative TMA cores, negative/low expression was observed in 275 cases (Supplementary Fig. 1G), while 399 cases (59%) showed high ISG15 expression (Supplementary Fig. 1H).

High expression of ISG15 protein was significantly associated with LVI positivity and other features of poor prognosis including younger age at diagnosis, larger tumour size, high grade, poor NPI, lack of expression of ER and PR and HER2 positivity (Table 3). Moreover, when we distributed the protein expression of ISG15 according to BC tumour IHC subtypes, high protein expression of ISG15 showed a significant association with ductal no special type (NST) BC tumour compared to lobular BC type ($p = 0.003$) (Table 3). Furthermore, when we compared ISG15 protein expression with BC progression-associated markers, high ISG15 protein expression was significantly associated with the high expression of P53, Ki67, EGFR and CD44, and high stromal immune markers of CD8, FOXP3 and CD68. However, it

| Gene names | METABRIC cohort | TCGA cohort |
|------------|----------------|-------------|
|            | Correlation value | $p$ value | Correlation value | $p$ value |
| **EMT-related genes** |
| CDH1       | $-0.034$ | 0.127 | 0.032 | 0.353 |
| CDH2       | 0.010  | 0.650 | 0.004 | 0.912 |
| TGFBI      | 0.041  | 0.068 | 0.065 | 0.056 |
| TWIST2     | $-0.152$ | $< 0.001$ | 0.033 | 0.329 |
| TWIST1     | $-0.042$ | 0.061 | 0.014 | 0.688 |
| ZEB2       | $-0.103$ | $< 0.001$ | $-0.038$ | 0.268 |
| ZEB1       | $-0.168$ | $< 0.001$ | $-0.044$ | 0.197 |
| SLUG       | $-0.142$ | $< 0.001$ | $-0.002$ | 0.956 |
| SNAIL      | 0.057  | 0.012 | 0.011 | 0.738 |
| NFKB1      | $-0.107$ | $< 0.001$ | $-0.005$ | 0.889 |
| LLGL2      | 0.102  | $< 0.001$ | 0.068 | 0.047 |
| GSK3B      | 0.211  | $< 0.001$ | $-0.042$ | 0.216 |
| CRUMB1     | $-0.018$ | 0.422 | $-0.012$ | 0.727 |
| CTNNB1     | $-0.165$ | $< 0.001$ | $-0.010$ | 0.040 |
| **MMPs-related genes** |
| MMP9       | 0.218  | $< 0.001$ | 0.030 | 0.035 |
| MMP11      | 0.152  | $< 0.001$ | 0.116 | 0.001 |
| MMP13      | 0.055  | 0.004 | 0.023 | 0.023 |
| MMP14      | 0.065  | 0.015 | 0.008 | 0.854 |
| MMP15      | 0.096  | $< 0.001$ | 0.044 | 0.198 |
| MMP20      | 0.050  | 0.025 | 0.016 | 0.639 |
| MMP21      | 0.045  | 0.047 | 0.097 | 0.005 |
| MMP25      | 0.076  | 0.003 | 0.011 | 0.746 |
| MMP28      | 0.248  | $< 0.001$ | 0.099 | 0.004 |

Significant correlations are in bold

Table 2 Correlation of high ISG15 mRNA expression with mRNA expression of EMT- and MMPs-related genes
Fig. 1 Patients' outcomes of Breast cancer survival on Transcriptomic level. a Cumulative survival of BC patients stratified by ISG15 mRNA expression in the METABRIC cohort. b Cumulative survival of BC patients stratified by ISG15 mRNA expression in the KM-Plotter cohort. c Cumulative survival of BC patients ISG15 mRNA expression in the TCGA cohort. d Cumulative survival of BC patients stratified by ISG15 mRNA expression in the METABRIC-restricted LVI-positive cohort. e Cumulative survival of BC patients stratified by ISG15 mRNA expression in the METABRIC-restricted HER2-positive cohort. f Cumulative survival of BC patients stratified by ISG15 mRNA expression in the TCGA-restricted LVI-positive cohort. g Cumulative survival of BC patients stratified by ISG15 mRNA expression in the TCGA-restricted HER2-positive cohort.

Fig. 2 Differential gene expression and pathway analysis. a Overlapping differentially expressed genes associated with high ISG15 mRNA expression. Cases depicting (I) overexpressed differentially expressed genes associated with high ISG15 mRNA on both METABRIC and TCGA restricted on Luminal B and HER2-positive cohorts. (II) Overlapping downregulated differentially expressed genes associated with High ISG15 mRNA on both METABRIC and TCGA restricted on Luminal B and HER2-positive cohorts. DGE: differentially expressed gene, (↓): downregulated genes, (↑) overexpressed genes. b The enriched biological process generated by the common 490 overexpressed genes based on high ISG15 mRNA expression on both METABRIC and TCGA restricted on Luminal B and HER2-positive cohorts.
showed negative association with tumour E-cadherin expression (Table 3).

Outcome analysis showed an inverse association between ISG15 protein expression and survival; high expression was associated with shorter BCSS ($p=0.008$; Fig. 3a). Multivariate analysis demonstrated that high protein expression of ISG15 was associated with shorter BCSS ($p=0.026$, Hazard ratio, 1.3, 95% CI 1.0–1.6), independent of other established prognostic factors including LVI, tumour size, histological grade, ER and HER2 status (Table 4).

When we stratified the Nottingham BC IHC cohort based on the LVI and HER2 status, high protein expression of ISG15 was associated with poor BCSS in the LVI-positive survival cases ($p=0.005$, Fig. 3b), and in the HER2-positive survival cases ($p=0.046$; Fig. 3c) subgroups, similar of poor survival trend were observed for LVI-negative survival cases and HER2-negative survival cases, but it did not reach statistical significant ($p > 0.05$, Supplementary Fig. 2E and F, respectively).

| Parameters                        | ISG15 protein expression | | $p$ value |
|-----------------------------------|--------------------------|---|----------------|
|                                   | Low: $N$ (%) | High: $N$ (%) |               |
| Tumour size                       |              |               |               |
| ≤ 2.0 cm                          | 144 (45)     | 178 (55)      | **0.044**     |
| > 2.0 cm                          | 127 (37)     | 216 (63)      |               |
| Nodal status                      |              |               |               |
| Negative                          | 393 (52)     | 369 (48)      | 0.192         |
| Positive                          | 165 (43)     | 219 (57)      |               |
| Histological grade                |              |               |               |
| 1                                 | 43 (51)      | 42 (49)       | **0.002**     |
| 2                                 | 104 (47)     | 117 (53)      |               |
| 3                                 | 128 (35)     | 238 (65)      |               |
| Tumour histological subtypes      |              |               |               |
| Ductal (NST)                      | 216 (39)     | 336 (71)      | **0.003**     |
| Lobular                           | 43 (61)      | 28 (39)       |               |
| Medullary-like                    | 11 (79)      | 3 (21)        |               |
| Special type                      | 10 (37)      | 17 (63)       |               |
| Lymphovascular invasion           |              |               |               |
| Negative                          | 164 (44)     | 210 (56)      | **<0.001**    |
| Positive                          | 62 (30)      | 144 (70)      |               |
| Nottingham prognostic index      |              |               |               |
| Good prognostic group             | 91 (51)      | 88 (49)       | **0.005**     |
| Moderate prognostic group         | 134 (38)     | 220 (62)      |               |
| Poor prognostic group             | 46 (35)      | 86 (65)       |               |
| Age                               |              |               |               |
| ≤ 50                              | 92 (36)      | 163 (64)      | **0.034**     |
| > 50                              | 179 (44)     | 232 (56)      |               |
| Oestrogen receptor                |              |               |               |
| Negative                          | 49 (30)      | 133 (73)      | **<0.001**    |
| Positive                          | 222 (46)     | 263 (54)      |               |
| Progesterone receptor             |              |               |               |
| Negative                          | 97 (34)      | 186 (66)      | **0.008**     |
| Positive                          | 165 (45)     | 205 (55)      |               |
| Human epidermal growth factor receptor 2 | 243 (44) | 313 (56) | **<0.001** |
| Negative                          | 19 (21)      | 73 (79)       |               |
| Positive                          | 58 (29)      | 141 (71)      | **0.001**     |
| P53                               |              |               |               |
| Negative                          | 201 (45)     | 250 (55)      | **0.001**     |
| Positive                          | 58 (29)      | 141 (71)      |               |
| Ki67                              |              |               |               |
| Negative                          | 95 (46)      | 111 (54)      | **0.008**     |
| Positive                          | 120 (35)     | 226 (65)      |               |
| E-Cadherin                        |              |               |               |
| Negative                          | 109 (36)     | 268 (64)      | **0.005**     |
| Positive                          | 109 (48)     | 120 (52)      |               |

Significant correlations are in bold.

### Table 3 (continued)

| Parameters                        | ISG15 protein expression | | $p$ value |
|-----------------------------------|--------------------------|---|----------------|
|                                   | Low: $N$ (%) | High: $N$ (%) |               |
| N-Cadherin                        |              |               |               |
| Negative                          | 52 (38)      | 84 (62)       | 0.904         |
| Positive                          | 151 (39)     | 238 (61)      |               |
| Basal-phenotype                   |              |               |               |
| Negative                          | 361 (79)     | 96 (21)       | **0.010**     |
| Positive                          | 246 (71)     | 102 (29)      |               |
| Epithelial growth factor receptor |              |               |               |
| Negative                          | 222 (43)     | 298 (57)      | **0.03**      |
| Positive                          | 43 (32)      | 90 (68)       |               |
| CD8                               |              |               |               |
| Negative                          | 116 (44)     | 147 (56)      | **0.013**     |
| Positive                          | 84 (33)      | 167 (67)      |               |
| CD44                              |              |               |               |
| Negative                          | 76 (43)      | 100 (57)      | **0.005**     |
| Positive                          | 44 (28)      | 72 (72)       |               |
| FOXP3                             |              |               |               |
| Negative                          | 86 (47)      | 99 (53)       | **0.019**     |
| Positive                          | 125 (36)     | 222 (64)      |               |
| CD68                              |              |               |               |
| Negative                          | 85 (47)      | 96 (53)       | **0.008**     |
| Positive                          | 114 (35)     | 212 (65)      |               |
| IHC subtypes                      |              |               |               |
| Luminal A                         | 100 (45)     | 124 (55)      | **<0.001**    |
| Luminal B                         | 50 (33)      | 100 (67)      |               |
| Her2 enriched                     | 26 (20)      | 103 (80)      |               |
| TNBC                              | 19 (21)      | 73 (79)       |               |

Outcome analysis showed an inverse association between ISG15 protein expression and survival; high expression was associated with shorter BCSS ($p=0.008$; Fig. 3a). Multivariate analysis demonstrated that high protein expression of ISG15 was associated with shorter BCSS ($p=0.026$, Hazard ratio, 1.3, 95% CI 1.0–1.6), independent of other established prognostic factors including LVI, tumour size, histological grade, ER and HER2 status (Table 4).
Discussion

The differences in the morphological and molecular features of BC that determine behaviour, outcome and response to therapy are key characteristics that pose challenges in the management of BC patients. One of these challenges is the role of LVI in BC and understanding the underlying molecular mechanisms and drivers of LVI as potential therapeutic targets [1]. LVI is an essential process in the metastatic cascade that needs further studies. ISG15 expression is upregulated in various cancers, including breast [43], hepatocellular [44], lung [45], prostate [46] and bladder [47] cancers. However, the association between ISG15 and BC progression, particularly its role in LVI, yet remains to be defined. Our study indicates a significant correlation between high ISG15 levels and not only LVI but also with other features of aggressive tumour behaviour including high tumour grade, large tumour size, hormone receptor negativity and overexpression of HER2, the immune cell markers, MMPs and the BC stem cell markers in addition to poor patient outcome. The association between high expression of ISG15 and nodal status in the METABRIC cohort also supports its ability to contribute in BC invasion and metastasis. These results are in accordance with several previous studies, which demonstrated that ISG15 is significantly associated with cancer progression [17, 43–46]. Although in our study some variation in the association between ISG15 expression and clinicopathological variables such as nodal status, this can be attributed to the difference in the nature of cohort, convoluted post-transcriptional mechanisms or perhaps due to the substantial differences in in vivo half-lives of proteins [48, 49].

As observed in our study, elevated ISG15 expression is an independent factor of HER2 expression indicating that targeting ISG15 may be an attractive treatment option for HER2-positive and/or hormone receptor-negative tumour which is accompanied with severe type of BC that has no target therapy yet as they mainly showed resistance to hormonal pathway drugs [50, 51]. In mouse BC models, the presence of ISG15 showed a significant impact in therapeutic experiments via controlling CD8 expression in both primary and metastatic burden [44]. In the current study, there is a high immune response illustrated by high expression of CD8, FOXP3 and CD68, which play an important role in tumour microenvironment and immune response, to ISG15 protein expression which may also support the role
of ISG15 in controlling tumour microenvironment in BC. It is well known that the tumour microenvironment has an essential role in stromal infiltration, invasion and development of LVI [52]. Additionally, ISG15 mRNA association with MMPs indicates the role in tumour progression as they have the ability to reorganise the extracellular matrix and prepare the microenvironment to produce cytokines that enhance cancer cell migration and proliferation [53]. Our data are in accordance with the previous studies for ISG15 in BC which indicated that ISG15 is significantly associated with cancer development and metastasis [8, 54].

When investigating the correlation between ISG15 mRNA expression and well-established EMT transcription factors, the results revealed a negative correlation with CTNNB1, CDH1; however, a positive association was shown with LLGL2. These findings indicate that high ISG15, at both transcriptomic and proteomic levels, involves in promoting tumour cell migration and enhancing the LVI process. This may occur by activating the ISGylation that inhibits cancer cell-stabilising proteins through F-actin activation, which might also correlate with inducing proliferative proteins such as P53, as our data allude [45, 55]. Furthermore, during metastasis, high levels of ISG15 might enhance a cooperative signalling by employing fibronectin-binding integrins such as αVβ3 and/or α5β1 to maintain high ISG15 levels. These integrins might trigger GTPases is resulting in activation or polymerisation of F-actin networks and stress fibres, which are necessary to stimulate the cell migration elements such as membrane protrusions, cell contractility and adhesion enforcement [8]. CTNNB1 plays an important role in tumour cells adhesion and maintains them together via controlling the cell growth and adhesion between cells [56]. Prompting of LLGL2 plays a key role in EMT activation and was positively associated with high ISG15 mRNA expression. In addition, we have previously reported that downregulation of E-cadherin (CDH1), which was negatively correlated with high protein expression of ISG15, has an important role in EMT activation, migration and invasion in BC by regulating Wnt and PI3K signalling [38]. Moreover, elevated levels of N-cadherin (CDH2), which increases the production of MMP9 to initiate the ideal environment for migratory tumour cells by rupturing the basement membrane in the tumour primary site, would eventually promote the migration process [57]. However, the last scenario might not necessarily be speculated in our study because no significant association was detected between ISG15 levels and CDH2. This study presented that high ISG15 at the transcriptomic (METABRIC cohort) and proteomic level was associated with EGFR, which can control EMT, migration and invasion [58]. Collectively speaking, the increased levels of LLGL2, EGFR and decreased level in CDH1, recorded in the current study, promote EMT and cancer cell migration in BC [9].

Hence, the association between ISG15 and loss of CDH1 may result in a reciprocal inhibitory mechanism promoting cell migration and invasion, which may imply an indirect role of ISG15 in LVI.

In the whole BC cohort, high expression of ISG15 protein was an independent prognostic marker for worse BCSS. Among defined BC molecular subgroups, high ISG15 protein expression was observed to have the lowest survival rate in HER2-enriched BC. HER2 BC type was considered as a model in this study because it is an aggressive cancer that strongly associated with cancer cell migration and metastasis. One of the LVI prerequisites is the presence of specialised protrusions namely filopodia or lamellipodia to degrade the basement membrane through polymerisation of F-actin chain [59]. Therefore, targeting candidate biomarkers that modulate F-actin in cancer cells may help tailoring the treatment strategy [60–62]. It was reported that ISG15 pathway induces BC cell conformational change leading to increase the tumour cell motility and metastatic ability through F-actin and microtubule filament modulation [9].

In this study, the data of DEGs and pathway analysis have supported the proposed role of high ISG15 association with epithelial cell migration particularly for Her2 and luminal B subtypes. This could explain the reflection of poor prognosis and tumour development when ISG15 is highly expressed. Therefore, targeting ISG15 pathway may potentially help to find new avenues that can be useful to precisely inhibit the tumour progression using personalised medicines. Therefore, further gene ontology analyses to other IHC subtypes are recommended to better understand the ISG15 role in all BC subtypes.

The crosstalk between tumour cells and tumour microenvironment is well known as a complex process. Several of non-tumour cell factors contribute to this process and may play a critical role by inducing tumour aggressiveness and tumour cells’ migration ability into the lymphatic vessels and cause LVI. Therefore, further mechanistic studies are warranted to understand the underlying mechanisms of LVI. Furthermore, ISG15 protein might be expressed in other cells; however, this is beyond the scope of this study which focuses mainly on the expression in tumour epithelial cells. Likewise, appropriate assessment for other type of cells in TMA is challenging as our TMAs were constructed primarily to incorporate tumour epithelial cells so the microenvironment may not be wholly representative.

In conclusion, our findings provide evidence that increased ISG15 at the transcriptomic and proteomic levels is strongly associated with LVI positivity and poor patient outcome in BC. Further functional in vivo and in vitro studies are warranted to identify its underlying mechanistic role and its therapeutic potential.
Acknowledgements The authors are part of the PathLAKE digital pathology consortium. Yousif Kariri is supported and funded by Shaqra University, Shaqra, Kingdom of Saudi Arabia.

Funding This research was supported and funded by the Saudi Arabia Ministry of Education Shaqra University. The authors are part of the PathLAKE digital pathology consortium. These new Centres are supported by a £50m investment from the Data to Early Diagnosis and Precision Medicine strand of the government’s Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI).

Data availability The authors confirm the data that have been used in this work are available on reasonable request.

Compliance with ethical standards

Conflict of interest The authors have no conflicts of interest to declare.

Ethical approval This work obtained ethics approval by the North West—Greater Manchester Central Research Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), reference number 15/NW/0685. We can declare that this study is complying with Helsinki declaration.

Research involving human participants and/or animals This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent All patients included in this study were consented.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Aleskandary MA, Sonbul SN, Mukherjee A, Rakha EA (2015) Molecular mechanisms underlying lymphovascular invasion in invasive breast cancer. Pathobiology 82(3–4):113–123. https://doi.org/10.1159/000433583
2. Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, Macmillan D, Ellis IO (2012) The prognostic significance of lymphovascular invasion in invasive breast cancer. Cancer 118(15):3670–3680. https://doi.org/10.1002/cncr.26711
3. Zhang S, Zhang D, Yi S, Gong M, Lu C, Cai Y, Tang X, Zou L (2017) The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 8(2):2863–2873. https://doi.org/10.18632/oncotarget.13752
4. Liu YL, Saraf A, Lee SM, Zhong X, Hibshoo H, Kalinsky K, Connolly EP (2016) Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 157(3):555–564. https://doi.org/10.1007/s10549-016-3837-5
5. Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani R, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandary MA, Fujii T, Shirabe K, Caldas C, Ashankuty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA (2019) A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer 120(12):1129–1136. https://doi.org/10.1038/s41416-019-0486-6
6. Kadota K, Nakai Y, Shimizu K (2008) A weighted average difference method for detecting differentially expressed genes from microarray data. Algorithms Molecular Biol 3:8. https://doi.org/10.1186/1748-7188-3-8
7. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. https://doi.org/10.1073/pnas.0506580102
8. Hermann MR, Jakobson M, Colo GP, Rognoni E, Jakobson M, Kupatt C, Posern G, Fassler R (2010) Integrins synergise to induce expression of the MRTF-A-SRF target gene ISG15 for promoting cancer cell invasion. J Cell Sci 123(7):1391–1403. https://doi.org/10.1242/jcs.177592
9. Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S (2012) ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood, NJ) 237(1):38–49. https://doi.org/10.1258/ebm.2011.011236
10. Okumura F, Okumura AJ, Uematsu K, Hatakeyama S, Zhang DE, Kamura T (2013) Activation of double-stranded RNA-activated protein kinase (PKR) by interferon-stimulated gene 15 (ISG15) modification down-regulates protein translation. J Biol Chem 288(4):2839–2847. https://doi.org/10.1074/jbc.M112.401851
11. Okumura F, Zou W, Zhang DE (2007) ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev 21(3):255–260. https://doi.org/10.1101/gad.1521607
12. D’Cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC (1996) Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 93(1):211–215. https://doi.org/10.1073/pnas.93.1.211
13. Bogunovic D, Boisson-Dupuis S, Casanova JL (2013) ISG15: leading a double life as a secreted molecule. Exp Mol Med 45:e18. https://doi.org/10.1038/emm.2013.36
14. Villarreal DO, Wise MC, Siefert RJ, Yan J, Wood LM, Weiner DB (2015) Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity. Mol Ther 23(10):1653–1662. https://doi.org/10.1038/mt.2015.120
15. Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC (2018) ISG15 promotes ERK1 ISGylation, CD8+ T cell activation and suppresses ovarian cancer progression. Cancers. https://doi.org/10.3390/cancers10120464
16. Fan JB, Miyauuchi-Ishida S, Arimoto K, Liu D, Yan M, Liu CW, Gyoryffy B, Zhang DE (2015) Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proc Natl Acad Sci USA 112(46):14313–14318. https://doi.org/10.1073/pnas.1505690112
17. Chen YL, Wu WL, Jang CW, Yen YC, Wang SH, Tsai FY, Shen YY, Chen YW (2019) Interferon-stimulated gene 15 modulates cell migration by interacting with Rac1 and contributes to lymph node metastasis of oral squamous cell carcinoma cells. Oncogene 38(23):4480–4495. https://doi.org/10.1038/s41388-019-0731-8
18. Zuo C, Sheng X, Ma M, Xia M, Ouyang L (2016) ISG15 in the tumorigenesis and treatment of cancer: an emerging role in malignancies of the digestive system. Oncotarget 7(45):74393–74409. https://doi.org/10.18632/oncotarget.11911

19. Curtis C, Shah SP, Chin SF, Tarushvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiva S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowitz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352. https://doi.org/10.1038/nature10983

20. Ciriello G, Gatza ML, Beck AH, Willkerson MD, Rhie SK, Pastore A, Zhang H, Mclellan M, Yau C, Kandoth C, Bowbly R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033

21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring complex cancer genomics data. Cancer Discov 2(5):401–404. https://doi.org/10.1158/2159-8290.cd-11-0095

22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https://doi.org/10.1126/scisignal.2004088

23. Gyofry B, Lanzczyk A, Eklund AC, Denkert C, Buczdesz J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725–731. https://doi.org/10.1007/s10549-009-0674-9

24. Kariri YA, Joseph C, Kurozumi S, Toss MS, Alsaleem M, Raafat ND (2013) Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. Breast Cancer Res Treat. 123(3):725–731. https://doi.org/10.1007/s10549-009-0674-9

25. Rakha EA, Agarwal D, Green AR, Ashankathy I, Ellis IO, Ball G, Alskandarany MA (2017) Prognostic stratification of oestrogen receptor-Positive HER2-negative lymph node-negative class of breast cancer. Histopathology 70(4):622–631. https://doi.org/10.1111/his.13108

26. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO (2015) Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2):93–99. https://doi.org/10.1136/jclinpath-2014-202571

27. Green AR, Alskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA (2016) MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer 114(8):917–928. https://doi.org/10.1038/bjc.2016.46

28. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbon PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907–922. https://doi.org/10.1043/1543-2165-134.6.907

29. Muftah AA, Alskandarany MA, Al-Kaabi MM, Sonbul SN, Diez-Rodriguez M, Nolan CC, Caldas C, Ellis IO, Rakha EA, Green AR (2017) Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Res Treat 164(2):341–348. https://doi.org/10.1007/s10549-017-4270-0

30. Rolland P, Spendlove I, Madjid Z, Rakha EA, Patel P, Ellis IO, Durrant L (2007) The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 120(6):1311–1317. https://doi.org/10.1002/ijc.22430

31. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46(6):685–693. https://doi.org/10.1111/j.1365-2559.2005.02156.x

32. Ahmed MA, Alskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO (2012) A CD44+/CD24− phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 133(3):979–995. https://doi.org/10.1007/s10549-011-1865-8

33. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl MM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelve C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nolan TO, Pharoah PD, Caldas C (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25(8):1536–1543. https://doi.org/10.1093/annonc/mdu191

34. Mahmoud SM, Lee AH, Paich EC, Macmillan RD, Ellis IO (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159–163. https://doi.org/10.1136/jclinpath-2011-200355

35. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikila P, Heikkinnen T, Nevanlinna H, Akslen LA, Begin LR, Foukles WD, Couch FJ, Wang X, Cafiourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha EA, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WP, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7(5):e1000279. https://doi.org/10.1371/journal.pmed.1000279

36. Abd El-Rehim DM, Ball G, Pinder SE, Rakha EA, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. https://doi.org/10.1002/ijc.21004

37. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archiv Pathol Lab Med 109(8):716–721

38. Alsaleem M, Toss MS, Joseph C, Alskandarany MA, Kurozumi S, Alshankity I, Ogden A, Rida PCG, Ellis IO, Anjia R, Green AR, Mongan NP, Rakha EA (2019) The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. Mod Pathol 32(7):967–976. https://doi.org/10.1038/s41377-9-01909-9
39. Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110(8):803–811. https://doi.org/10.1093/jnci/djy1129

40. Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, Usadel B (2012) RoBiNA: a user-friendly, integrated software solution for RNA-Seq-based transcriptomics. Nucleic Acids Res 40(1):W622-627. https://doi.org/10.1093/nar/gks540

41. Oliveros JC (2020) Venn diagrams for comparing lists. https://bioinformatc.ca/tools/venny_old/venny.php.

42. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z (2009) GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinform 10:48. https://doi.org/10.1186/1471-2105-10-48

43. Cruz-Ramos E, Macias-Silva M, Sandoval-Hernandez A, Tecalco-Cruz AC (2019) Non-muscle myosin IA is post-translationally modified by interferon-stimulated gene 15 in breast cancer cells. Int J Biochem Cell Biol 107:14–26. https://doi.org/10.1016/j.biocel.2018.12.002

44. Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y (2012) The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother 61(5):689–700. https://doi.org/10.1007/s00262-011-1129-9

45. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E (2008) UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 7(12):3780–3788. https://doi.org/10.1158/1535-7163.mct-08-0753

46. Satake H, Tamura K, Furihata M, Anchi T, Sakoda H, Kawada C, Iiyama T, Ashida S, Shuin T (2010) The ubiquitin-like molecule, ISG15 are associated with the progression and metastasis of breast cancer by a meta-analysis integrating three microarray datasets. Pathol Oncol Res. https://doi.org/10.18632/oncotarget.2199

47. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF (2006) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94(10):1465–1471. https://doi.org/10.1038/sj.bjc.6603099

48. Baldi P, Long AD (2001) A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics (Oxford, England) 17(6):509–519. https://doi.org/10.1093/bioinformatics/17.6.509

49. Liu Y, Beyer A, Aebersold R (2016) On the dependency of cellular protein levels on mRNA abundance. Cell 165(3):535–550. https://doi.org/10.1016/j.cell.2016.03.014

50. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119–131. https://doi.org/10.1016/j.ccr.2011.05.026

51. Meisel JL, Venur VA, Gnant M, Carey L (2018) Evolution of targeted therapy in breast cancer: where precision medicine began.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.